Fidabio

Fidabio, based in Denmark, is a company specializing in advanced biophysical analysis through its innovative FIDA technology, which enables rapid multiparameter analysis of biological molecules for research and pharmaceutical applications. Based in Soborg, Denmark, and founded in 2013 by CEO Brian Sorensen and CSO Henrik Jensen, Fida Biosystems ApS focuses on biophysical analysis solutions. The company specializes in providing life science tools. In December 2025, Fidabio raised EUR 5 million in series A funding led by Fahraeus Startup and Growth, with participation from Export and Investment Fund of Denmark.

The round was part of a larger EUR 5 million series A funding. Fidabio specializes in advanced biophysical analysis through its core product, the FIDA (Flow Induced Dispersion Analysis) technology. This instrument enables researchers to conduct fast, multiparameter in-solution analysis, facilitating the assessment of over ten essential biophysical parameters in a single assay. FIDA's unique capabilities allow for the detailed characterization of various biological molecules, including proteins and membrane proteins, without the need for surface immobilization.

The technology is designed to assist in drug binding studies, solubility screening, and the characterization of complex biological systems, making it particularly valuable in the pharmaceutical and biotechnology sectors. The company serves a diverse client base, including academic institutions, core facilities, and research organizations across Europe and North America, where they apply FIDA technology to enhance their understanding of protein behavior and interactions. Fidabio generates revenue primarily through the sale of its FIDA instruments and associated consumables, which are vital for conducting biophysical assays. The company operates on a direct-to-consumer model, selling to research institutions and laboratories that require advanced analytical capabilities for biophysical characterization.

Clients typically purchase the FIDA systems outright along with ongoing consumable supplies necessary for continued operation. This transactional structure enables Fidabio to establish long-term relationships with customers who rely on the technology for critical research applications, while also providing opportunities for service contracts and technical support. The company’s flagship product, the Fida 1, is central to its offerings, catering specifically to the needs of customers engaged in high-throughput screening and complex biophysical analyses. In December 2025, Fidabio raised EUR 5 million in Series A funding, which will be utilized to prepare for a Series B round and support expansion and scaling efforts.

The company aims to launch new products to enhance its offerings and is exploring opportunities to expand into additional European and North American markets by 2026.